Literature DB >> 29113188

Zoledronic acid sensitizes rhabdomyosarcoma cells to cytolysis mediated by human γδ T cells.

Ling-Ling Sun1, Zheng-Liang Zhang1,2, Ying-Jun Li3, Sheng-Dong Wang1, Heng-Yuan Li1, Bing-Hao Li1, Ting Zhu1, Zhao-Ming Ye1.   

Abstract

Rhabdomyosarcoma (RMS) is the most common type of soft-tissue sarcoma in children. Immunotherapy has been proposed as a treatment for this deadly tumor. In the present study, the cytotoxicity of ex vivo expanded γδ T cells on RMS cell lines was evaluated and the molecular interactions involved were investigated. γδ T cells were expanded in vitro using peripheral blood mononuclear cells from 5 healthy donors and were stimulated with zoledronic acid (Zol) and interleukin 2. RMS cell lines RD and A-673 were used as target cells. The cytotoxicity of the γδ T cells against RMS was assessed in vitro and in vivo. γδ T cells were cytotoxic to RMS cells. Importantly, Zol markedly increased their cytotoxic potential. RMS cells treated with Zol-stimulated γδ T cells to produce interferon γ. γδ T cell-mediated cytotoxicity was primarily through the T cell receptor-dependent signaling pathway in blocking studies. Transfer of γδ T cells together with Zol into nude mice induced the regression of RD tumor xenotransplants. The results of the present study provide the rationale for the clinical evaluation of γδ T cells in RMS.

Entities:  

Keywords:  cytotoxicity; immunotherapy; rhabdomyosarcoma; zoledronic acid; γδ T cells

Year:  2017        PMID: 29113188      PMCID: PMC5656036          DOI: 10.3892/ol.2017.6894

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  23 in total

Review 1.  Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer.

Authors:  Marina Ferrarini; Elisabetta Ferrero; Lorenzo Dagna; Alessandro Poggi; Maria Raffaella Zocchi
Journal:  Trends Immunol       Date:  2002-01       Impact factor: 16.687

2.  Activation of V gamma 9V delta 2 T cells by NKG2D.

Authors:  Bladimiro Rincon-Orozco; Volker Kunzmann; Philine Wrobel; Dieter Kabelitz; Alexander Steinle; Thomas Herrmann
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

3.  Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells.

Authors:  Meng Liu; Ling-Ling Sun; Ying-Jun Li; Heng-Yuan Li; Jian Zhang; Bing-Hao Li; Zhao-Ming Ye
Journal:  Int Immunopharmacol       Date:  2015-06-10       Impact factor: 4.932

4.  Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.

Authors:  Stephen R Mattarollo; Tony Kenna; Mie Nieda; Andrew J Nicol
Journal:  Cancer Immunol Immunother       Date:  2007-01-31       Impact factor: 6.968

5.  Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens.

Authors:  Y Kato; Y Tanaka; F Miyagawa; S Yamashita; N Minato
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

6.  Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.

Authors:  Miki Sakamoto; Jun Nakajima; Tomohiro Murakawa; Takeshi Fukami; Yukihiro Yoshida; Tomonori Murayama; Shinichi Takamoto; Hirokazu Matsushita; Kazuhiro Kakimi
Journal:  J Immunother       Date:  2011-03       Impact factor: 4.456

Review 7.  Adoptive immunotherapy against sarcomas.

Authors:  Giulia Mesiano; Valeria Leuci; Lidia Giraudo; Loretta Gammaitoni; Fabrizio Carnevale Schianca; Michela Cangemi; Ramona Rotolo; Sonia Capellero; Ymera Pignochino; Giovanni Grignani; Massimo Aglietta; Dario Sangiolo
Journal:  Expert Opin Biol Ther       Date:  2014-12-16       Impact factor: 4.388

Review 8.  gammadelta T cells in cancer immunotherapy: current status and future prospects.

Authors:  Shubhada Chiplunkar; Swati Dhar; Daniela Wesch; Dieter Kabelitz
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

9.  Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.

Authors:  Odile Oberlin; Annie Rey; Elizabeth Lyden; Gianni Bisogno; Michael C G Stevens; William H Meyer; Modesto Carli; James R Anderson
Journal:  J Clin Oncol       Date:  2008-05-10       Impact factor: 44.544

10.  Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation.

Authors:  Karin Schilbach; Mohammed Alkhaled; Christian Welker; Franziska Eckert; Gregor Blank; Hendrik Ziegler; Marco Sterk; Friederike Müller; Katja Sonntag; Thomas Wieder; Heidi Braumüller; Julia Schmitt; Matthias Eyrich; Sabine Schleicher; Christian Seitz; Annika Erbacher; Bernd J Pichler; Hartmut Müller; Robert Tighe; Annick Lim; Stephen D Gillies; Wolfgang Strittmatter; Martin Röcken; Rupert Handgretinger
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

View more
  2 in total

1.  Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL-NKG2D Axis.

Authors:  Zhan Wang; Zenan Wang; Shu Li; Binghao Li; Lingling Sun; Hengyuan Li; Peng Lin; Shengdong Wang; Wangsiyuan Teng; Xingzhi Zhou; Zhaoming Ye
Journal:  Front Immunol       Date:  2018-06-01       Impact factor: 7.561

Review 2.  Function of γδ T cells in tumor immunology and their application to cancer therapy.

Authors:  Jang Hyun Park; Heung Kyu Lee
Journal:  Exp Mol Med       Date:  2021-03-12       Impact factor: 8.718

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.